Results 171 to 180 of about 131,813 (277)

Public Health Achievements in Rwanda: A 21st Century Transformation

Public Health Challenges, Volume 5, Issue 2, June 2026.
This narrative review examines Rwanda's post‐2000 public health transformation using the WHO health system building blocks. It shows how strategic governance, universal health coverage via mutuelle de santé, community health workers, and digital health tools have driven substantial gains in maternal/child health, infectious disease control, and ...
Niyibizi Julius, Mugisha John, Nizeyimana Emmanuel   +2 more
wiley   +1 more source

Vaccination Coverage at Birth in Brazil: Spatial and Temporal Trends in the Impact of COVID-19 on Uptake of BCG and Hepatitis B Vaccines. [PDF]

Vaccines (Basel)
Alves YM, Berra TZ, Tavares RBV, Zini N, Ferreira QR, Andrade LKA, Tártaro AF, Pelodan MEP, Vigato BF, Silveira BK, Assumpção ALBNM, Popolin MAP, Curvo PA, Protti-Zanatta S, Serrano-Gallardo MDP, Arcêncio RA, Palha PF, Ballestero JGA.   +17 more
europepmc   +1 more source

Hepatitis C Vaccines, Antibodies, and T Cells. [PDF]

Front Immunol, 2018
Shoukry NH.
europepmc   +1 more source

When Public Health Becomes the Weapon: Current and Prospective Consequences of the Genocide in Gaza

World Medical &Health Policy, Volume 18, Issue 2, June 2026.
ABSTRACT Catastrophic humanitarian conditions during the 2023–2025 genocide in Gaza have caused a public health crisis of exceptional magnitude. This article summarizes key short‐ and long‐term health consequences for Gaza's civilian population and outlines priorities for recovery.
Therese Alexandra Evald, Nanna Gram Ahlmark, Clara Barfod Parellada, Andreea Micula, Caroline Klint Johannesen, Dana Bdier, Fayez Mahamid, Hilde Lausund, Jane Brandt Sørensen, Maha Aon, Majd Qannita, Maren Johanne Heilskov Rytter, Nanna Maaløe, Nina Jøranson, Sara Aakre Faradonbeh, Vibeke Brix Christensen, Waseem Alzaanin, Sigurd Lauridsen, Helle Timm, Frederik Schou‐Juul   +19 more
wiley   +1 more source

Post-marketing safety study to evaluate pregnancy outcomes among recipients of hepatitis B vaccines. [PDF]

Hum Vaccin Immunother
Bruxvoort KJ, Sy LS, Slezak J, Ackerson BK, Qian L, Qiu S, Solano Z, Reynolds K.   +7 more
europepmc   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 362-368, June 2026.
ABSTRACT Aim To present an overview of personalized cancer vaccines currently undergoing clinical development, aiming to enhance awareness and promote collaboration among academic, commercial researchers, and non‐profit communities. Methods A dataset of 78 clinical trials for personalized cancer vaccines was generated using ClinicalTrials.gov database ...
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Safety of Hepatitis B Vaccines (Monovalent or as Part of Combination) in Preterm Infants: A Systematic Review. [PDF]

Vaccines (Basel)
Tee QW, Odisho R, Purcell E, Purcell R, Buttery J, Nold-Petry CA, Nold MF, Nold MF, Malhotra A.   +8 more
europepmc   +1 more source

Do we need better hepatitis B vaccines? [PDF]

Indian J Med Res, 2017
Gerlich WH.
europepmc   +1 more source

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye, Yunzheng Li, Yanjun Lu, Yanchao Xu, Laizhu Zhang, Yican Zhu, Huan Li, Binghua Li, Min Zhou, Decai Yu   +9 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source